BlackRock, Inc. Increases Stake in Oruka Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing an increased ownership stake in Oruka Therapeutics, Inc. As of September 30, 2025, BlackRock holds 2,197,517 shares of Oruka Therapeutics' common stock, representing a 4.5% ownership. This marks a significant increase from its previous holdings, with a value change of $38,092,421.16 and a shares change of 208,637. The filing indicates that BlackRock acquired these shares in the ordinary course of business and not with the intent to influence control of the issuer. The filing also includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.